IP Library › Granted Patent US 12,441,709
Granted Patent B2
US 12,441,709 · App. 18/225,966 · Granted Oct 14, 2025

Therapeutic compounds

Inventor: Barrie Phillip Martin (Manchester, GB)
Assignee: Indivior UK Limited
C07D401/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,441,709
App. No.
18/225,966
Granted
Oct 14, 2025
Kind
B2
Abstract

The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.

Claims (21)

1. A method of treating a disease or condition selected from substance dependence, alcohol dependence, and nicotine dependence;

said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound which is selected from:

N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl)pyrazin-2-yl] amino} propan-2-yl] pyridine-2-carboxamide; and

N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl)pyrimidin-2-yl] amino} propan-2-yl] pyridine-2-carboxamide;

or a pharmaceutically acceptable salt or solvate thereof.

2. The method of claim 1 , wherein the compound is:

N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl) pyrazin-2-yl] amino} propan-2-yl] pyridine-2-carboxamide;

or a pharmaceutically acceptable salt or solvate thereof.

3. The method of claim 1 , wherein the compound is:

N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl) pyrimidin-2-yl]amino} propan-2-yl]pyridine-2-carboxamide;

or a pharmaceutically acceptable salt or solvate thereof.

4. The method of claim 1 , wherein the disease or condition is a substance dependence selected from cocaine, opiate, cannabis, alcohol, and prescription drug dependence.

5. The method of claim 4 , wherein the disease or condition is opiate dependence.

6. The method of claim 1 , wherein the compound is administered in combination with one or more other agents useful in the treatment of addictive disorders.

7. The method of claim 6 , wherein the one or more other agents useful in the treatment of addictive disorders are selected from buprenorphine, naloxone, naltrexone, and nalmefene.

8. The method of claim 7 , wherein the one or more other agents useful in the treatment of addictive disorders is buprenorphine.

9. The method of claim 1 , wherein the compound is administered orally.

10. The method of claim 1 , wherein the compound is administered in a solid oral dosage form.

11. The method of claim 1 , wherein the compound is administered in a dosage of between about 0.5 mg to about 500 mg of said compound.

12. The method of claim 11 , wherein the compound is administered in a dosage of between about 0.5 mg to about 100 mg of said compound.

13. The method of claim 11 , wherein the compound is administered in a dosage of 50, 100, 200 or 500 mg of said compound.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: PIPER SANDLER FINANCE, LLC
To: INDIVIOR INC.; INDIVIOR UK LIMITED
Reel/Frame 074114/0582 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME AND ADDRESS PREVIOUSLY RECORDED ON REEL 68342 FRAME 653. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 17, 2025
From: C4X DISCOVERY LIMITED
To: INDIVIOR UK LIMITED
Reel/Frame 073958/0904 →
SECURITY INTEREST Recorded Nov 13, 2024
From: INDIVIOR INC.; INDIVIOR UK LIMITED
To: PIPER SANDLER FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 069254/0413 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2024
From: MARTIN, BARRIE P.
To: C4X DISCOVERY LIMITED
Reel/Frame 068342/0610 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2024
From: C4X DISCOVERY LIMITED
To: INDIVIOR UK LIMITED (CO.)
Reel/Frame 068342/0653 →
Priority Claims (1)
GB 1601703 · Jan 29, 2016 · national
Continuity (4)
Continuation 17459598 · Aug 27, 2021
Division 16860572 · Apr 28, 2020
Continuation 16073429
Related Publication 20240076282A1 · Mar 7, 2024
References Cited (123)
US 5968965A · Dinsmore et al. · 1999 [cited by applicant]
US 6066738A · Dinsmore et al. · 2000 [cited by applicant]
US 6727267B2 · Jaen et al. · 2004 [cited by applicant]
US 6861448B2 · Brouillette et al. · 2005 [cited by applicant]
US 6905739B2 · Cherkaoui et al. · 2005 [cited by applicant]
US 6953857B2 · Nazare et al. · 2005 [cited by applicant]
US 7067665B2 · Nazare et al. · 2006 [cited by applicant]
US 7338950B2 · Kelly et al. · 2008 [cited by applicant]
US 7468367B2 · Coulton et al. · 2008 [cited by applicant]
US 7501538B2 · Mjalli et al. · 2009 [cited by applicant]
US 7544699B2 · Mjalli et al. · 2009 [cited by applicant]
US 7872133B2 · Ohmoto et al. · 2011 [cited by applicant]
US 8039674B2 · Habashita et al. · 2011 [cited by applicant]
US 8653305B2 · Habashita et al. · 2014 [cited by applicant]
US 8987271B2 · Cardone et al. · 2015 [cited by applicant]
US 10011595B2 · Kim et al. · 2018 [cited by applicant]
US 10611760B2 · Blaney et al. · 2020 [cited by applicant]
US 10696654B2 · Martin · 2020 [cited by examiner]
US 11130746B2 · Martin · 2021 [cited by applicant]
US 11753398B2 · Martin · 2023 [cited by applicant]
US 12024509B2 · Blaney et al. · 2024 [cited by applicant]
US 20020198195A1 · Nazare et al. · 2002 [cited by applicant]
US 20040266732A1 · Galvez et al. · 2004 [cited by applicant]
US 20050080087A1 · Pendri et al. · 2005 [cited by applicant]
US 20080262046A1 · Coleman et al. · 2008 [cited by applicant]
US 20110212975A1 · Kao et al. · 2011 [cited by applicant]
US 20110263662A1 · Aissaoui et al. · 2011 [cited by applicant]
US 20120316147A1 · Bissantz et al. · 2012 [cited by applicant]
US 20170291897A1 · Blaney et al. · 2017 [cited by applicant]
US 20200255404A1 · Martin · 2020 [cited by applicant]
US 20200270247A1 · Blaney et al. · 2020 [cited by applicant]
US 20210395227A1 · Martin · 2021 [cited by applicant]
EP 1349847A1 · 2003 [cited by applicant]
EP 1456203A1 · 2004 [cited by applicant]
EP 1637521A1 · 2006 [cited by applicant]
EP 1698335A1 · 2006 [cited by applicant]
EP 1760071A1 · 2007 [cited by applicant]
EP 1979341A1 · 2008 [cited by applicant]
EP 2462138A1 · 2012 [cited by applicant]
EP 2532661A1 · 2012 [cited by applicant]
EP 2730570A1 · 2014 [cited by applicant]
EP 2891489A1 · 2015 [cited by applicant]
EP 2891492A1 · 2015 [cited by applicant]
GB 240685A · 1925 [cited by applicant]
JP 2002326980A · 2002 [cited by applicant]
JP 2003012625A · 2003 [cited by applicant]
JP 2006526653A · 2006 [cited by applicant]
JP 2007537300A · 2007 [cited by applicant]
JP 2008533151A · 2008 [cited by applicant]
JP 2008239617A · 2008 [cited by applicant]
JP 2010534626A · 2010 [cited by applicant]
JP 2012056871A · 2012 [cited by applicant]
JP 2013216634A · 2013 [cited by applicant]
WO WO97027852A1 · 1997 [cited by applicant]
WO WO0147862A1 · 2001 [cited by applicant]
WO WO0177091A2 · 2001 [cited by applicant]
WO WO200191558A1 · 2001 [cited by applicant]
WO WO2003051872A1 · 2003 [cited by applicant]
WO WO05014532A1 · 2005 [cited by applicant]
WO WO05014533A2 · 2005 [cited by applicant]
WO WO2005032493A2 · 2005 [cited by applicant]
WO WO2005090345A1 · 2005 [cited by applicant]
WO WO2005095327A1 · 2005 [cited by applicant]
WO WO06038594A1 · 2006 [cited by applicant]
WO WO2006110626A1 · 2006 [cited by applicant]
WO WO03006628A3 · 2006 [cited by applicant]
WO WO2007088999A1 · 2007 [cited by applicant]
WO WO2007126934A2 · 2007 [cited by applicant]
WO WO08002671A2 · 2008 [cited by applicant]
WO WO2008061781A1 · 2008 [cited by applicant]
WO WO2009011775A1 · 2009 [cited by applicant]
WO WO2009022311A2 · 2009 [cited by applicant]
WO WO2010012795A1 · 2010 [cited by applicant]
WO WO2010086366A1 · 2010 [cited by applicant]
WO WO2011015037A1 · 2011 [cited by applicant]
WO WO2011073316A1 · 2011 [cited by applicant]
WO WO2012021837A2 · 2012 [cited by applicant]
WO WO2012088438A1 · 2012 [cited by applicant]
WO WO2013048942A1 · 2013 [cited by applicant]
WO WO2013066833A1 · 2013 [cited by applicant]
WO WO2013076230A1 · 2013 [cited by applicant]
WO WO2013158928A2 · 2013 [cited by applicant]
WO WO2014044738A1 · 2014 [cited by applicant]
WO WO2014159591A1 · 2014 [cited by applicant]
WO WO2015188073A1 · 2015 [cited by applicant]
WO WO2016034882A1 · 2016 [cited by applicant]
WO WO2016100161A1 · 2016 [cited by applicant]
Abbas et al., “Comprehensive Behavioral Analysis of Male Ox1r−/− Mice Showed Implication of Orexin Receptor-1 in Mood, Anxiety, and Social Behavior,” Frontiers in Behavioral Neuroscience, 9: Article 324 pp. 1-10 (2015). [cited by applicant]
Baimel et al., “Orexin/hypocretin role in reward: implications for opioid and other addictions,” British Journal of Pharmacology, 172: 334-348 (2015). [cited by applicant]
Benting et al., “Preparation of arylalkylpyrazolecarboxamide derivatives and analogs for use as fungicides,” Calpus, (2011). [cited by applicant]
Boss et al., “Recent Trends in Orexin Research—2010 to 2015,” Bioorganic & Medicinal Chemistry Letters, 25:2875-2887 (2015). [cited by applicant]
Boss, “Orexin Receptor Antogonists—A Patent Review (2010 to Aug. 2014),” Expert Opinion, 24(12):1367-1381 (2014). [cited by applicant]
Braga et I., “Mild and efficient one-pot synthesis of chiral ß-chalcogen amides via 2-oxazoline ring-opening reaction mediated by indium,” Journal of Organometallic Chemistry, 693:3563-3655 (2008). [cited by applicant]
Cai et al., “Antagonists of the Orexin Receptors,” Expert Opinion, 16(5):631-646 (2006). [cited by applicant]
CAS Registry No. 1115194-20-1 (2009). [cited by applicant]
Clapp, “Reactions of ethylenimines with ammonia and amines,” CAPLUS 1948:15572 (1948). [cited by applicant]
Coleman et al., “Discovery of [(2R,5R0-5-{[(5-Flouropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): A Dual Orexin Receptor Antagonist with Potent Sleep-Promoting P… [cited by applicant]
Coleman et al., “Discovery of Dual Orexin Receptor Antagonists (DORAs) for the Treatment of Insomnia,” Currrent Topics in Medicinal Chemistry, 11:696-725 (2011). [cited by applicant]
Coleman et al., “Orexin Receptor Antagonists: A Review of Promising Compounds Patented Since 2006,” Expert Opinion, 20(3):307-324 (2010). [cited by applicant]
Dubey et al., “Suvorexant: The first orexin receptor antagonist to treat insomnia,” J Pharmacol Pharmacother, 6(2): 118-121 (2015). [cited by applicant]
Imperatore et al., “Effects of the Radical Savenger AVS on Behavioral and BBB Changes After Experimental Subarachnoid Hemmorrhage,” Life Sciences, 66(9): 779-790 (2000). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2017/051960 dated Mar. 8, 2017. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/GB2015/052546 dated Oct. 29, 2015. [cited by applicant]
Kaufmann et al., “First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist,” British Journal of Clinical Pharmacology, 86(7): 1377-1386 (2020). [cited by applicant]
Lebold et al., “Selective Orexin Receptor Antagonists,” Bioorganic & Medicinal Chemistry Letters, 23:4761-4769 (2013). [cited by applicant]
Mahler et al., “Multiple roles for orexin/hypocretin in addiction,” Progress in Brain Research, 198: 49 pages (2012). [cited by applicant]
Malherbe et al., “Mapping the Binding Pocket of Dual Antagonist almorexant to Human Orexin 1 and Orexin 2 Receptors: Comparison with the Selective OX1 Antagonist SB-674042 and the Selective OX2 Antagonist N-Ethyl-2[(6-m… [cited by applicant]
McManus et al., “Coupling of bulky, electron-deficient partners in aryl amination in the preparation of tridentate bis(oxazoline) ligands for asymmetric catalysis,” J Org Chem, 67:8566-8573 (2002). [cited by applicant]
Mirbolouk et al., “Chronic orexin-1 receptor blockage attenuates depressive behaviors and provokes PSD-95 expression in a rat model of depression”, Behavioral Brain Research 437: 7 pages (2022). [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/459,598 dated May 2, 2023. [cited by applicant]
Piccoli et al., “Role of Orexin-1 Receptor Mechanisms on Compulsive Food Consumption in a Model of Binge Eating in Female Rats,” Neuropsychopharmacology, 37: 1999-2011 (2012). [cited by applicant]
Rasmussen et al., “NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted,” Neuropsychopharmacology, 44: 657-659 (2019). [cited by applicant]
Roecker et al., “Orexin Receptor Antagonists: Medicinal Chemistry and Therapeutic Potential,” Current Topics in Medicinal Chemistry, 8:977-987 (2008). [cited by applicant]
Salvadore et al., “Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans,” Translational Psychiatry, 10: 308 pp. 1-10 (2020). [cited by applicant]
Scott et al., “Hcrtr1 and 2 signaling differentially regulates depression-like behaviors”, Behavioral Brain Research 222(2): 289-294 (2011). [cited by applicant]
Sekste et al., “Increase in the Level of Orexin Receptor 1 ( OXJ R) mRNA in the Brain Structures of Rats Prone to Impulsivity in Behavior”, Biomedical Chemistry, 6(1):38-44 (2022). [cited by applicant]
Sharf et al., “Role of orexin/hypocretin in dependence and addiction,” Brain Res, 1314C (15 pages) (2010). [cited by applicant]
Thannickal et al., “Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy,” Science Translational Medicine, 10: Article eaao4953 pp. 1-13… [cited by applicant]
U.K. Search Report for Application No. GB1601703.0 dated Nov. 9, 2016. [cited by applicant]
United Kingdom Search Report for United Kingdom Application No. GB 1415569.1 dated May 8, 2015. [cited by applicant]
Vickers et al., “Effects of Lisdexamfetamine in a rat model of binge-eating”, Journal of Psychopharmacology, 29(12): 1290-1307 (2015). [cited by applicant]
Written Opinion issued by the Intellectual Property Office of Singapore in corresponding Application No. 11201701715P, dated Nov. 20, 2017. [cited by applicant]
Zhang et al., “Direct borylation of primary C—H bonds in functionalized molecules by palladium catalysis,” Angew Chem Int Et, 53:3899-3903 (2014). [cited by applicant]